Christian B. Dinneen-Long
General Counsel at GLYCOMIMETICS, INC.
Christian B. Dinneen-Long active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GLYCOMIMETICS, INC. | General Counsel | 2019-04-28 | - |
| Corporate Secretary | 2019-04-28 | - |
Career history of Christian B. Dinneen-Long
Former positions of Christian B. Dinneen-Long
| Companies | Position | Start | End |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | General Counsel | - | - |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | General Counsel | - | - |
| Medimmune, Inc. | General Counsel | - | - |
Training of Christian B. Dinneen-Long
| Chicago-Kent College of Law | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| General Counsel | 4 |
| Corporate Secretary | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
